Silo Pharma, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Silo Pharma, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $72.1K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $72.1K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $72.1K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $72.1K | Mar 25, 2024 |
| FY2020 | Dec 31, 2020 | $40.9K | May 17, 2021 |
| FY2020 | Dec 31, 2019 | $40.6K | May 17, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.8K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $66.3K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $66.3K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $66.3K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $66.3K | Mar 24, 2023 |
| FY2020 | Dec 31, 2020 | ($135.2K) | May 17, 2021 |
| FY2020 | Dec 31, 2019 | $13.2K | May 17, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.23M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.39M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.70M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($3.91M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $3.90M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($3.04M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($1.01M) | May 17, 2021 |
| FY2019 | Dec 31, 2018 | ($969.5K) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $356.5K | Apr 4, 2019 |
| FY2013 | Dec 31, 2012 | ($39.4K) | Mar 31, 2014 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.28M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($4.71M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.86M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($3.63M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($2.74M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($2.20M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($930.4K) | May 17, 2021 |
| FY2019 | Dec 31, 2018 | ($594.2K) | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($490.9K) | Apr 4, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.16M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.37M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $845.1K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.29M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $693.9K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $26.3K | Mar 28, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $390.1K | Mar 25, 2024 |
| FY2023 | Dec 31, 2022 | $227.3K | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $163.0K | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $50.2K | Mar 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.66M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($3.83M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($3.22M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($3.50M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($2.28M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($1.16M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($794.3K) | May 17, 2021 |
| FY2019 | Dec 31, 2018 | $272.6K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | ($284.6K) | Apr 4, 2019 |
| FY2013 | Dec 31, 2013 | ($181.6K) | Mar 31, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.61M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $7.41M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $7.75M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.64M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $10.49M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.43M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $493.8K | May 17, 2021 |
| FY2019 | Dec 31, 2018 | $855.4K | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | $1.64M | Apr 4, 2019 |
| FY2013 | Dec 31, 2013 | $2.21M | Mar 31, 2014 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.30M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.38M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.57M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.30M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $1.43M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $146.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $116.7K | May 17, 2021 |
| FY2013 | Dec 31, 2013 | $18.7K | Mar 31, 2014 |
| FY2013 | Dec 31, 2012 | $41.5K | Mar 31, 2014 |
| FY2012 | Dec 31, 2011 | $3.5K | Mar 5, 2013 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $5.03M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $6.18M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $10.34M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $9.06M | Mar 25, 2024 |
| FY2022 | Dec 31, 2020 | $1.28M | Mar 24, 2023 |
| FY2021 | Dec 31, 2019 | ($22.9K) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $407.4K | May 17, 2021 |
| FY2019 | Dec 31, 2017 | $1.20M | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $846.5K | Apr 4, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.49M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($15.26M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($10.87M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($7.17M) | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | ($3.26M) | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | ($5.76M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($2.66M) | May 17, 2021 |
| FY2019 | Dec 31, 2018 | ($1.64M) | Mar 20, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.75M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.91M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.52M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $11.37M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | $9.84M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.13M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $111.8K | May 17, 2021 |
| FY2020 | Dec 31, 2018 | $336.7K | May 17, 2021 |
| FY2019 | Dec 31, 2017 | $294.6K | Mar 20, 2020 |
| FY2018 | Dec 31, 2016 | $579.2K | Apr 4, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 4, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 4, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 28, 2025 |
| FY2021 | Dec 31, 2021 | 0 | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | 0 | Mar 28, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Apr 4, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 4, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13.32M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 4.48M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 2.91M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 3.16M | Mar 25, 2024 |
| FY2022 | Dec 31, 2021 | 1.97M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 85.14M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 23.60M | May 17, 2021 |
| FY2019 | Dec 31, 2018 | 23.42M | Mar 20, 2020 |
| FY2018 | Dec 31, 2017 | 50.08M | Apr 4, 2019 |
| FY2013 | Dec 31, 2013 | 40.61M | Mar 31, 2014 |